New Delhi: The trade union government expects the Covid-19 vaccine Zydus Cadila-free needle, Zycov-D is available starting from the first week of October.
Furthermore, the decision whether all children or only those who have a co-morbidities will be given a Covid-19 vaccine in priority has not been taken, the government said on Thursday.
Zycov-D Zycov-D which was accidentally developed on Friday received approval for authorization of emergency use from drug regulators, making it the first vaccine in the country to be given to the age group 12-18 years.
In the type of negotiation in terms of pricing and when the government plans to buy Zycov-D, Uni Health Secretary Rajesh Bhushan said, “Come to negotiations, what we understand from the media report and our involvement with vaccine manufacturing companies is that they will be in The position to provide this vaccine from the first week of October.
“So we are in talks with them and when we crystallize the terms and conditions of our procurement will share it with you,” he said at a press conference.
On whether children with comorbidity will be prioritized for vaccinations, Bhushan says whether all children must be taken on priority or children with comorbidity must be taken is a problem where the committee stands in Covid-19 Ntagi makes recommendations.
“Recommendations have not been made and so made, then Ntagi calls and recommends it to the government and then the process is concluded and the decision is taken,” he said.
Covishield, Covaxin and Vacine Sputnik v are given only on those above 18 years and unlike Zycov-D, the three doses, this is given in two doses.
The Biotechnology Department (DBT) has said that ZYCOV-D is the world’s first DNA-based vaccine against Coronavirus and when injected produce a protein surge in the SARS-COV-2 virus and raises immune responses, which plays an important role, which plays an important role.
In protection from disease and virus permits.
It is said that the temporary results of the clinical trial phase-III in more than 28,000 volunteers showed primary efficacy of 66.6 percent for positive RT-PCR symptoms.
This has been the biggest vaccine trial so far in India for Covid-19, DBT said.
Vaccines have shown a strong immunogenicity and tolerability profile and safety profiles in the one and two adaptive phases of clinical trials.
Both phases one / two and phase three clinical trials have been monitored by the independent data safety monitoring board, he added.